Cyclin-dependent kinase-associated protein Cks2 is associated with bladder cancer progression

Journal of International Medical Research

Volumn 39, Issue 2, 2011, Pages 533-540

  Chen, R ^a   Feng, C ^a   Xu, Y ^a  

^a SHANGHAI JIAO TONG UNIVERSITY AFFILIATED SIXTH PEOPLE S HOSPITAL   (China)

Author keywords

Bladder cancer; Cancer progression; Cyclin dependent kinase associated protein Cks2; Gene expression

Indexed keywords

CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE ASSOCIATED PROTEIN CKS2; DEAD BOX PROTEIN; DEAD BOX PROTEIN 5; FATTY ACID BINDING PROTEIN; FATTY ACID BINDING PROTEIN 5; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; MURINE MAMMARY TUMOR INTEGRATION SITE 6; POLY(A) BINDING PROTEIN CYTOPLASMIC 1; POLYADENYLIC ACID BINDING PROTEIN; PROTEIN; SPLICING FACTOR 3B SUBUNIT 1; TRANSGELIN; TROPOMYOSIN; TROPOMYOSIN 2 BETA; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLADDER CANCER; CANCER GROWTH; CANCER INVASION; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; MALE; OBSERVATIONAL STUDY; REAL TIME POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SUPERFICIAL CANCER; UPREGULATION;

EID: 79955673221     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323001103900222     Document Type: Article

References (37)

1. Jemal A, Siegel R, Xu J, et al: Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300.
2. Soloway MS, Sofer M, Vaidya A: Contemporary management of stage T1 transitional cell carcinoma of the bladder. J Urol 2002; 167: 1573-1583.
3. Saad A, Hanbury DC, McNicholas TA, et al: A study comparing various noninvasive methods of detecting bladder cancer in urine. BJU Int 2002; 89: 369-373.
4. Stein JP, Lieskovsky G, Cote R, et al: Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 2001; 19: 666-675.
5. Matsumoto M, Kawakami K, Enokida H, et al: CpG hypermethylation of human four-and-ahalf LIM domains 1 contributes to migration and invasion activity of human bladder cancer. Int J Mol Med 2010; 26: 241-247.
6. Mori K, Enokida H, Kagara I, et al: CpG hypermethylation of collagen type I hh2 contributes to proliferation and migration activity of human bladder cancer. Int J Oncol 2009; 34: 1593-1602.
7. Kawakami K, Enokida H, Tachiwada T, et al: Identification of differentially expressed genes in human bladder cancer through genomewide gene expression profiling. Oncol Rep 2006; 16: 521-531.
8. Bolenz C, Lotan Y: Translational research in bladder cancer: from molecular pathogenesis to useful tissue biomarkers. Cancer Biol Ther 2010; 10: 407-415.
9. Bryan RT, Tselepis C: Cadherin switching and bladder cancer. J Urol 2010; 184: 423-431.
10. McConkey DJ, Lee S, Choi W, et al: Molecular genetics of bladder cancer: emerging mechanisms of tumor initiation and progression. Urol Oncol 2010; 28: 429-440.
11. Patra D, Dunphy WG: Xe-p9, a Xenopus Suc1/Cks protein, is essential for the Cdc2-dependent phosphorylation of the anaphasepromoting complex at mitosis. Genes Dev 1998; 12: 2549-2559.
12. 2/M regulators. J Biol Chem 1999; 274: 36839-36842.
13. Martinsson-Ahlzén HS, Liberal V, Grünenfelder B, et al: Cyclin-dependent kinase-associated proteins Cks1 and Cks2 are essential during early embryogenesis and for cell cycle progression in somatic cells. Mol Cell Biol 2008; 28: 5698-5709.
14. Wakui M, Shiigai T: Urinary tract cancer screening through analysis of urinary red blood cell volume distribution. Int J Urol 2000; 7: 248-253.
15. Herr HW, Schneider M: Outpatient flexible cystoscopy in men: a randomized study of patient tolerance. J Urol 2001; 165: 1971-1972.
16. Wu XR: Urothelial tumorigenesis: a tale of divergent pathways. Nat Rev Cancer 2005; 5: 713-725.
17. Shariat SF, Chade DC, Karakiewicz PI, et al: Combination of multiple molecular markers can improve prognostication in patients with locally advanced and lymph node positive bladder cancer. J Urol 2010; 183: 68-75.
18. Siegenthaler G, Hotz R, Chatellard-Gruaz D, et al: Characterization and expression of a novel human fatty acid-binding protein: the epidermal type (E-FABP). Biochem Biophys Res Commun 1993; 190: 482-487.
19. O'Shaughnessy RF, Seery JP, Celis JE, et al: PAFABP, a novel marker of human epidermal transit amplifying cells revealed by 2D protein gel electrophoresis and cDNA array hybridisation. FEBS Lett 2000; 486: 149-154.
20. Kannan-Thulasiraman P, Seachrist DD, Mahabeleshwar GH, et al: Fatty acid-binding protein 5 and PPARp///are critical mediators of epidermal growth factor receptor-induced carcinoma cell growth. J Biol Chem 2010; 285: 19106-19115.
21. Fang LY, Wong TY, Chiang WF, et al: Fatty-acidbinding protein 5 promotes cell proliferation and invasion in oral squamous cell carcinoma. J Oral Pathol Med 2010; 39: 342-348.
22. Grange T, de Sa CM, Oddos J, et al: Human mRNA polyadenylate binding protein: evolutionary conservation of a nucleic acid binding motif. Nucleic Acids Res 1987; 15: 4771-4787.
23. Craig AW, Haghighat A, Yu AT, et al: Interaction of polyadenylate-binding protein with the eIF4G homologue PAIP enhances translation. Nature 1998; 392: 520-523.
24. Hloch P, Schiedner G, Stahl H: Complete cDNA sequence of the human p68 protein. Nucleic Acids Res 1990; 18: 3045.
25. Iggo R, Gough A, Xu W, et al: Chromosome mapping of the human gene encoding the 68-kDa nuclear antigen (p68) by using the polymerase chain reaction. Proc Natl Acad Sci USA 1989; 86: 6211-6214.
26. Wilson BJ, Bates GJ, Nicol SM, et al: The p68 and p72 DEAD box RNA helicases interact with HDAC1 and repress transcription in a promoter-specific manner. BMC Mol Biol 2004; 5: 11.
27. Nicol SM, Causevic M, Prescott AR, et al: The nuclear DEAD box RNA helicase p68 interacts with the nucleolar protein fibrillarin and colocalizes specifically in nascent nucleoli during telophase. Exp Cell Res 2000; 257: 272-280.
28. Miyazaki S, Imatani A, Ballard L, et al: The chromosome location of the human homolog of the mouse mammary tumor-associated gene INT6 and its status in human breast carcinomas. Genomics 1997; 46: 155-158.
29. Wang C, Chua K, Seghezzi W, et al: Phosphorylation of spliceosomal protein SAP 155 coupled with splicing catalysis. Genes Dev 1998; 12: 1409-1414.
30. Zhu J, Bilan PJ, Moyers JS, et al: Rad, a novel Ras-related GTPase, interacts with skeletal muscle m-tropomyosin. J Biol Chem 1996; 271: 768-773.
31. Kobayashi R, Kubota T, Hidaka H: Purification, characterization, and partial sequence analysis of a new 25-kDa actin-binding protein from bovine aorta: a SM22 homolog. Biochem Biophys Res Commun 1994; 198: 1275-1280.
32. Assinder SJ, Au E, Dong Q, et al: A novel splice variant of the v-tropomyosin (TPM2) gene in prostate cancer. Mol Carcinog 2010; 49: 525-531.
33. Shields JM, Rogers-Graham K, Der CJ: Loss of transgelin in breast and colon tumors and in RIE-1 cells by Ras deregulation of gene expression through Raf-independent pathways. J Biol Chem 2002; 277: 9790-9799.
34. Yang Z, Chang YJ, Miyamoto H, et al: Transgelin functions as a suppressor via inhibition of ARA54-enhanced androgen receptor transactivation and prostate cancer cell growth. Mol Endocrinol 2007; 21: 343-358.
35. Urbanowicz-Kachnowicz I, Baghdassarian N, Nakache C, et al: Ckshs expression is linked to cell proliferation in normal and malignant human lymphoid cells. Int J Cancer 1999; 82: 98-104.
36. Giannopoulos A, Manousakas T, Gounari A, et al: Comparative evaluation of the diagnostic performance of the BTA stat test, NMP22 and urinary bladder cancer antigen for primary and recurrent bladder tumors. J Urol 2001; 166: 470-475.
37. Mahnert B, Tauber S, Kriegmair M, et al: Measurements of complement factor H-related protein (BTA-TRAK assay) and nuclear matrix protein (NMP22 assay)-useful diagnostic tools in the diagnosis of urinary bladder cancer? Clin Chem Lab Med 2003; 41: 104-110.